Global Androgenetic Alopecia Treatment Market
Global Androgenetic Alopecia Treatment Market

Androgenetic Alopecia Treatment Comprehensive Study by Type (Drugs (Minoxidil, Dutasteride, Finasteride and Others), Low-level Laser Therapy, Microneedling and Hair Transplantation, Others), Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Pharmacies, Online Pharmacies), End-user (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2026

Androgenetic Alopecia Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 218 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Androgenetic Alopecia Treatment Market?

It is estimated that androgenetic Alopecia affects up to 80% of men and 50% of women in the course of their life. Androgenetic alopecia is a common form of hair loss due to genetic reasons in both men and women. In this condition receding hairline and gradual disappearance of hair from the crown and frontal scalp. United States Food and Drug Administration (FDA) has approved only two drugs for the treatment of androgenetic alopecia that includes minoxidil and finasteride. Numerous new therapies are emerging or being studied as treatment options for androgenetic alopecia.

The market study is being classified by Type (Drugs (Minoxidil, Dutasteride, Finasteride and Others), Low-level Laser Therapy, Microneedling and Hair Transplantation and Others) and major geographies with country level break-up.

Histogen Inc. (United States), Daiichi-Sankyo Co., Ltd. (Japan), Lexington International LLC (United States), Vitabiotics (United Kingdom), Die Vita-Cos-Med Klett-Loch GmbH (Germany), PureTech Health (United States), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (United States), Dr. Reddy’s Laboratories (India), Follica, Inc. (United States), Cipla (India) and Johnson & Johnson (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Ales Group (France) and Ranbaxy Laboratories Ltd. (India).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Androgenetic Alopecia Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Androgenetic Alopecia Treatment market by Type, Application and Region.

On the basis of geography, the market of Androgenetic Alopecia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Androgenetic Alopecia among People
  • Development of New Diagnostic Centre and Hospitals
  • Increase in Healthcare Expenditure in Developing Regions such as China and India

Market Trend
  • Increased Awareness about Androgenetic Alopecia Treatment

Restraints
  • Lack of Complete Cure for Androgenetic Alopecia Treatment

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Development of Healthcare Infrastructure in Emerging Economies

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Androgenetic Alopecia Treatment Providers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Drugs (Minoxidil, Dutasteride, Finasteride and Others)
  • Low-level Laser Therapy
  • Microneedling and Hair Transplantation
  • Others
By Distribution Channel
  • Hospitals Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

By End-user
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Androgenetic Alopecia among People
      • 3.2.2. Development of New Diagnostic Centre and Hospitals
      • 3.2.3. Increase in Healthcare Expenditure in Developing Regions such as China and India
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Awareness about Androgenetic Alopecia Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Androgenetic Alopecia Treatment, by Type, Distribution Channel, End-user and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Androgenetic Alopecia Treatment (Value)
      • 5.2.1. Global Androgenetic Alopecia Treatment by: Type (Value)
        • 5.2.1.1. Drugs (Minoxidil, Dutasteride, Finasteride and Others)
        • 5.2.1.2. Low-level Laser Therapy
        • 5.2.1.3. Microneedling and Hair Transplantation
        • 5.2.1.4. Others
      • 5.2.2. Global Androgenetic Alopecia Treatment by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals Pharmacies
        • 5.2.2.2. Drug Stores
        • 5.2.2.3. Retail Pharmacies
        • 5.2.2.4. Online Pharmacies
      • 5.2.3. Global Androgenetic Alopecia Treatment by: End-user (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Androgenetic Alopecia Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Androgenetic Alopecia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Histogen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Daiichi-Sankyo Co., Ltd. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lexington International LLC (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Vitabiotics (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Die Vita-Cos-Med Klett-Loch GmbH (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. PureTech Health (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Dr. Reddy’s Laboratories (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Follica, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Cipla (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Johnson & Johnson (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Androgenetic Alopecia Treatment Sale, by Type, Distribution Channel, End-user and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Androgenetic Alopecia Treatment (Value)
      • 7.2.1. Global Androgenetic Alopecia Treatment by: Type (Value)
        • 7.2.1.1. Drugs (Minoxidil, Dutasteride, Finasteride and Others)
        • 7.2.1.2. Low-level Laser Therapy
        • 7.2.1.3. Microneedling and Hair Transplantation
        • 7.2.1.4. Others
      • 7.2.2. Global Androgenetic Alopecia Treatment by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals Pharmacies
        • 7.2.2.2. Drug Stores
        • 7.2.2.3. Retail Pharmacies
        • 7.2.2.4. Online Pharmacies
      • 7.2.3. Global Androgenetic Alopecia Treatment by: End-user (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Androgenetic Alopecia Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Androgenetic Alopecia Treatment: by Type(USD Million)
  • Table 2. Androgenetic Alopecia Treatment Drugs (Minoxidil, Dutasteride, Finasteride and Others) , by Region USD Million (2015-2020)
  • Table 3. Androgenetic Alopecia Treatment Low-level Laser Therapy , by Region USD Million (2015-2020)
  • Table 4. Androgenetic Alopecia Treatment Microneedling and Hair Transplantation , by Region USD Million (2015-2020)
  • Table 5. Androgenetic Alopecia Treatment Others , by Region USD Million (2015-2020)
  • Table 6. Androgenetic Alopecia Treatment: by Distribution Channel(USD Million)
  • Table 7. Androgenetic Alopecia Treatment Hospitals Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Androgenetic Alopecia Treatment Drug Stores , by Region USD Million (2015-2020)
  • Table 9. Androgenetic Alopecia Treatment Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 10. Androgenetic Alopecia Treatment Online Pharmacies , by Region USD Million (2015-2020)
  • Table 11. Androgenetic Alopecia Treatment: by End-user(USD Million)
  • Table 12. Androgenetic Alopecia Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 13. Androgenetic Alopecia Treatment Clinics , by Region USD Million (2015-2020)
  • Table 14. Androgenetic Alopecia Treatment Others , by Region USD Million (2015-2020)
  • Table 15. South America Androgenetic Alopecia Treatment, by Country USD Million (2015-2020)
  • Table 16. South America Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 17. South America Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 18. South America Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 19. Brazil Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 20. Brazil Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 21. Brazil Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 22. Argentina Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 23. Argentina Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 24. Argentina Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 25. Rest of South America Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 26. Rest of South America Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 27. Rest of South America Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 28. Asia Pacific Androgenetic Alopecia Treatment, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 30. Asia Pacific Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 31. Asia Pacific Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 32. China Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 33. China Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 34. China Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 35. Japan Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 36. Japan Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 37. Japan Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 38. India Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 39. India Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 40. India Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 41. South Korea Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 42. South Korea Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 43. South Korea Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 44. Taiwan Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 45. Taiwan Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 46. Taiwan Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 47. Australia Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 48. Australia Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 49. Australia Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 53. Europe Androgenetic Alopecia Treatment, by Country USD Million (2015-2020)
  • Table 54. Europe Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 55. Europe Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 56. Europe Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 57. Germany Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 58. Germany Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 59. Germany Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 60. France Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 61. France Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 62. France Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 63. Italy Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 64. Italy Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 65. Italy Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 66. United Kingdom Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 67. United Kingdom Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 68. United Kingdom Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 69. Netherlands Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 70. Netherlands Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 71. Netherlands Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 72. Rest of Europe Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 73. Rest of Europe Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 74. Rest of Europe Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 75. MEA Androgenetic Alopecia Treatment, by Country USD Million (2015-2020)
  • Table 76. MEA Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 77. MEA Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 78. MEA Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 79. Middle East Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 80. Middle East Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 81. Middle East Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 82. Africa Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 83. Africa Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 84. Africa Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 85. North America Androgenetic Alopecia Treatment, by Country USD Million (2015-2020)
  • Table 86. North America Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 87. North America Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 88. North America Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 89. United States Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 90. United States Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 91. United States Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 92. Canada Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 93. Canada Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 94. Canada Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 95. Mexico Androgenetic Alopecia Treatment, by Type USD Million (2015-2020)
  • Table 96. Mexico Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 97. Mexico Androgenetic Alopecia Treatment, by End-user USD Million (2015-2020)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Androgenetic Alopecia Treatment: by Type(USD Million)
  • Table 111. Androgenetic Alopecia Treatment Drugs (Minoxidil, Dutasteride, Finasteride and Others) , by Region USD Million (2021-2026)
  • Table 112. Androgenetic Alopecia Treatment Low-level Laser Therapy , by Region USD Million (2021-2026)
  • Table 113. Androgenetic Alopecia Treatment Microneedling and Hair Transplantation , by Region USD Million (2021-2026)
  • Table 114. Androgenetic Alopecia Treatment Others , by Region USD Million (2021-2026)
  • Table 115. Androgenetic Alopecia Treatment: by Distribution Channel(USD Million)
  • Table 116. Androgenetic Alopecia Treatment Hospitals Pharmacies , by Region USD Million (2021-2026)
  • Table 117. Androgenetic Alopecia Treatment Drug Stores , by Region USD Million (2021-2026)
  • Table 118. Androgenetic Alopecia Treatment Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 119. Androgenetic Alopecia Treatment Online Pharmacies , by Region USD Million (2021-2026)
  • Table 120. Androgenetic Alopecia Treatment: by End-user(USD Million)
  • Table 121. Androgenetic Alopecia Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 122. Androgenetic Alopecia Treatment Clinics , by Region USD Million (2021-2026)
  • Table 123. Androgenetic Alopecia Treatment Others , by Region USD Million (2021-2026)
  • Table 124. South America Androgenetic Alopecia Treatment, by Country USD Million (2021-2026)
  • Table 125. South America Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 126. South America Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 127. South America Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 128. Brazil Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 129. Brazil Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 130. Brazil Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 131. Argentina Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 132. Argentina Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 133. Argentina Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 134. Rest of South America Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 135. Rest of South America Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 136. Rest of South America Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 137. Asia Pacific Androgenetic Alopecia Treatment, by Country USD Million (2021-2026)
  • Table 138. Asia Pacific Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 139. Asia Pacific Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 140. Asia Pacific Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 141. China Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 142. China Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 143. China Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 144. Japan Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 145. Japan Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 146. Japan Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 147. India Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 148. India Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 149. India Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 150. South Korea Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 151. South Korea Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 152. South Korea Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 153. Taiwan Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 154. Taiwan Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 155. Taiwan Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 156. Australia Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 157. Australia Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 158. Australia Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 162. Europe Androgenetic Alopecia Treatment, by Country USD Million (2021-2026)
  • Table 163. Europe Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 164. Europe Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 165. Europe Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 166. Germany Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 167. Germany Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 168. Germany Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 169. France Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 170. France Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 171. France Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 172. Italy Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 173. Italy Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 174. Italy Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 175. United Kingdom Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 176. United Kingdom Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 177. United Kingdom Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 178. Netherlands Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 179. Netherlands Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 180. Netherlands Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 181. Rest of Europe Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 182. Rest of Europe Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 183. Rest of Europe Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 184. MEA Androgenetic Alopecia Treatment, by Country USD Million (2021-2026)
  • Table 185. MEA Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 186. MEA Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 187. MEA Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 188. Middle East Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 189. Middle East Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 190. Middle East Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 191. Africa Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 192. Africa Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 193. Africa Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 194. North America Androgenetic Alopecia Treatment, by Country USD Million (2021-2026)
  • Table 195. North America Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 196. North America Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 197. North America Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 198. United States Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 199. United States Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 200. United States Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 201. Canada Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 202. Canada Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 203. Canada Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 204. Mexico Androgenetic Alopecia Treatment, by Type USD Million (2021-2026)
  • Table 205. Mexico Androgenetic Alopecia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 206. Mexico Androgenetic Alopecia Treatment, by End-user USD Million (2021-2026)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Androgenetic Alopecia Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Androgenetic Alopecia Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Androgenetic Alopecia Treatment: by End-user USD Million (2015-2020)
  • Figure 7. South America Androgenetic Alopecia Treatment Share (%), by Country
  • Figure 8. Asia Pacific Androgenetic Alopecia Treatment Share (%), by Country
  • Figure 9. Europe Androgenetic Alopecia Treatment Share (%), by Country
  • Figure 10. MEA Androgenetic Alopecia Treatment Share (%), by Country
  • Figure 11. North America Androgenetic Alopecia Treatment Share (%), by Country
  • Figure 12. Global Androgenetic Alopecia Treatment share by Players 2020 (%)
  • Figure 13. Global Androgenetic Alopecia Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Androgenetic Alopecia Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Histogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Histogen Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Daiichi-Sankyo Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 19. Daiichi-Sankyo Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 20. Lexington International LLC (United States) Revenue, Net Income and Gross profit
  • Figure 21. Lexington International LLC (United States) Revenue: by Geography 2020
  • Figure 22. Vitabiotics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Vitabiotics (United Kingdom) Revenue: by Geography 2020
  • Figure 24. Die Vita-Cos-Med Klett-Loch GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Die Vita-Cos-Med Klett-Loch GmbH (Germany) Revenue: by Geography 2020
  • Figure 26. PureTech Health (United States) Revenue, Net Income and Gross profit
  • Figure 27. PureTech Health (United States) Revenue: by Geography 2020
  • Figure 28. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 29. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2020
  • Figure 30. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 32. Dr. Reddy’s Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 33. Dr. Reddy’s Laboratories (India) Revenue: by Geography 2020
  • Figure 34. Follica, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Follica, Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 37. Cipla (India) Revenue: by Geography 2020
  • Figure 38. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 39. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 40. Global Androgenetic Alopecia Treatment: by Type USD Million (2021-2026)
  • Figure 41. Global Androgenetic Alopecia Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 42. Global Androgenetic Alopecia Treatment: by End-user USD Million (2021-2026)
  • Figure 43. South America Androgenetic Alopecia Treatment Share (%), by Country
  • Figure 44. Asia Pacific Androgenetic Alopecia Treatment Share (%), by Country
  • Figure 45. Europe Androgenetic Alopecia Treatment Share (%), by Country
  • Figure 46. MEA Androgenetic Alopecia Treatment Share (%), by Country
  • Figure 47. North America Androgenetic Alopecia Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Histogen Inc. (United States)
  • Daiichi-Sankyo Co., Ltd. (Japan)
  • Lexington International LLC (United States)
  • Vitabiotics (United Kingdom)
  • Die Vita-Cos-Med Klett-Loch GmbH (Germany)
  • PureTech Health (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Merck & Co., Inc. (United States)
  • Dr. Reddy’s Laboratories (India)
  • Follica, Inc. (United States)
  • Cipla (India)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Ales Group (France) , Ranbaxy Laboratories Ltd. (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation